Symbol
| EDN2
| contributors: mct - updated : 19-03-2014
|
HGNC name
| endothelin 2
|
HGNC id
| 3177
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
|  
| gain of function
|
in basal cell carcinoma under control of Hedgehog signaling pathway | tumoral
|  
|  
|  
| loss of function
|
occurs frequently in colon cancers | |
Susceptibility
|
for essential hypertension |
Variant & Polymorphism
other
| the EDN2 A985 allele may be a risk factor for atrial fibrillation in patients with hypertrophic cardiomyopathy (Nagai 2007) |
|
|
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | urinary | | |
could represent a potential target for chemopreventive or neoadjuvant therapeutics for clear cell renal cell carcinoma |
| | | |
| Edn2 overexpression in the early embryo inhibits vascular development at midgestation, but Edn2 overexpression in developing skin and brain has no discernible effect on vascular structure | |
Edn2 overexpression in the developing mouse retina potently and specifically inhibits retinal angiogenesis and promotes the tip cell state |